Athira Pharma (LONA) Competitors

$10.33 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$10.48 +0.15 (+1.40%)

As of 05/22/2026 04:10 PM Eastern

LONA vs. IRD, PBYI, XFOR, CMPX, and FENC

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Opus Genetics (IRD), Puma Biotechnology (PBYI), X4 Pharmaceuticals (XFOR), Compass Therapeutics (CMPX), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Opus Genetics?

Athira Pharma (NASDAQ:LONA) and Opus Genetics (NASDAQ:IRD) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Opus Genetics has higher revenue and earnings than Athira Pharma. Opus Genetics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Opus Genetics	$14.20M	24.42	-$49.59M	-$1.33	N/A

In the previous week, Opus Genetics had 6 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Opus Genetics and 0 mentions for Athira Pharma. Opus Genetics' average media sentiment score of 0.40 beat Athira Pharma's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
Opus Genetics	Neutral

Athira Pharma presently has a consensus target price of $10.00, suggesting a potential downside of 3.19%. Opus Genetics has a consensus target price of $10.18, suggesting a potential upside of 139.01%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.80

Athira Pharma has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Opus Genetics' return on equity of -338.88% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Opus Genetics	-892.36%	-338.88%	-191.21%

Athira Pharma has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Opus Genetics beats Athira Pharma on 11 of the 16 factors compared between the two stocks.

How does Athira Pharma compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Athira Pharma has a consensus target price of $10.00, indicating a potential downside of 3.19%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Puma Biotechnology has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Puma Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

In the previous week, Puma Biotechnology's average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Athira Pharma	Neutral

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Puma Biotechnology has a net margin of 10.69% compared to Athira Pharma's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Athira Pharma	N/A	-381.01%	-225.74%

Summary

Puma Biotechnology beats Athira Pharma on 8 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for X4 Pharmaceuticals and 0 mentions for Athira Pharma. X4 Pharmaceuticals' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
X4 Pharmaceuticals	Neutral
Athira Pharma	Neutral

X4 Pharmaceuticals currently has a consensus price target of $8.50, indicating a potential upside of 110.40%. Athira Pharma has a consensus price target of $10.00, indicating a potential downside of 3.19%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

X4 Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Athira Pharma has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Athira Pharma	N/A	-381.01%	-225.74%

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

X4 Pharmaceuticals has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Summary

X4 Pharmaceuticals beats Athira Pharma on 11 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Compass Therapeutics had 7 more articles in the media than Athira Pharma. MarketBeat recorded 7 mentions for Compass Therapeutics and 0 mentions for Athira Pharma. Compass Therapeutics' average media sentiment score of 0.28 beat Athira Pharma's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Neutral
Athira Pharma	Neutral

Compass Therapeutics' return on equity of -39.75% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Athira Pharma	N/A	-381.01%	-225.74%

Compass Therapeutics currently has a consensus target price of $13.60, suggesting a potential upside of 557.00%. Athira Pharma has a consensus target price of $10.00, suggesting a potential downside of 3.19%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Compass Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Compass Therapeutics has higher revenue and earnings than Athira Pharma. Compass Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	438.57	-$66.49M	-$0.41	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Summary

Compass Therapeutics beats Athira Pharma on 12 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Adherex Technologies?

Athira Pharma (NASDAQ:LONA) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

In the previous week, Adherex Technologies had 14 more articles in the media than Athira Pharma. MarketBeat recorded 14 mentions for Adherex Technologies and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Adherex Technologies' score of -0.27 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Neutral
Adherex Technologies	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Athira Pharma currently has a consensus price target of $10.00, suggesting a potential downside of 3.19%. Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 55.09%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adherex Technologies	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Athira Pharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Adherex Technologies has higher revenue and earnings than Athira Pharma. Adherex Technologies is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Adherex Technologies	$44.64M	7.68	-$9.74M	-$0.29	N/A

Athira Pharma has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Summary

Adherex Technologies beats Athira Pharma on 10 of the 16 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$97.03M	$431.65M	$4.26B	$12.34B
Dividend Yield	N/A	N/A	5.93%	5.28%
P/E Ratio	-1.98	N/A	21.90	25.65
Price / Sales	N/A	326.53	180.55	86.31
Price / Cash	N/A	N/A	55.68	56.67
Price / Book	1.97	3.25	34.85	7.14
Net Income	-$105.61M	-$81.71M	$112.32M	$335.98M
7 Day Performance	2.38%	2.74%	3.52%	4.15%
1 Month Performance	24.01%	2.02%	3.56%	2.54%
1 Year Performance	N/A	N/A	15.78%	35.06%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	1.5606 of 5 stars	$10.33 flat	$10.00 -3.2%	N/A	$97.03M	N/A	N/A	40
IRD Opus Genetics	3.4943 of 5 stars	$4.29 -3.4%	$10.18 +137.3%	+317.6%	$361.40M	$14.20M	N/A	14	Gap Up
PBYI Puma Biotechnology	1.2964 of 5 stars	$7.05 +0.9%	N/A	+119.2%	$355.79M	$228.40M	14.69	200
XFOR X4 Pharmaceuticals	2.197 of 5 stars	$4.04 +7.2%	$8.50 +110.4%	+30.3%	$355.58M	$35.11M	N/A	80
CMPX Compass Therapeutics	3.2272 of 5 stars	$1.92 +1.6%	$13.60 +608.3%	-1.0%	$340.37M	$850K	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. IRD, PBYI, XFOR, CMPX, and FENC

How does Athira Pharma compare to Opus Genetics?

Summary

How does Athira Pharma compare to Puma Biotechnology?

Summary

How does Athira Pharma compare to X4 Pharmaceuticals?

Summary

How does Athira Pharma compare to Compass Therapeutics?

Summary

How does Athira Pharma compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. IRD, PBYI, XFOR, CMPX, and FENC

How does Athira Pharma compare to Opus Genetics?

Which has higher earnings and valuation, LONA or IRD?

Does the media prefer LONA or IRD?

Do analysts rate LONA or IRD?

Is LONA or IRD more profitable?

Which has more risk & volatility, LONA or IRD?

Do insiders & institutionals hold more shares of LONA or IRD?

Summary

How does Athira Pharma compare to Puma Biotechnology?

Do analysts recommend PBYI or LONA?

Which has stronger valuation and earnings, PBYI or LONA?

Which has more volatility & risk, PBYI or LONA?

Does the media refer more to PBYI or LONA?

Do insiders and institutionals believe in PBYI or LONA?

Is PBYI or LONA more profitable?

Summary

How does Athira Pharma compare to X4 Pharmaceuticals?

Does the media favor XFOR or LONA?

Do analysts recommend XFOR or LONA?

Which has more volatility and risk, XFOR or LONA?

Is XFOR or LONA more profitable?

Do insiders & institutionals believe in XFOR or LONA?

Which has stronger valuation and earnings, XFOR or LONA?

Summary

How does Athira Pharma compare to Compass Therapeutics?

Does the media favor CMPX or LONA?

Is CMPX or LONA more profitable?

Do analysts rate CMPX or LONA?

Which has more risk & volatility, CMPX or LONA?

Do institutionals & insiders hold more shares of CMPX or LONA?

Which has better valuation and earnings, CMPX or LONA?

Summary

How does Athira Pharma compare to Adherex Technologies?

Does the media prefer LONA or FENC?

Do institutionals and insiders hold more shares of LONA or FENC?

Do analysts prefer LONA or FENC?

Is LONA or FENC more profitable?

Which has better earnings and valuation, LONA or FENC?

Which has more volatility and risk, LONA or FENC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools